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Available online 18 August 2016Angelman syndrome (AS) is a rare genetic and neurological disorder presenting with seizures, developmental
delay, ataxia, and lack of speech. Previous studies have indicated that oxidative stress-dependent metabolic dys-
functionmay underlie the phenotypic deﬁcits reported in theASmousemodel.While the ketogenic diet (KD)has
been used to protect against oxidative stress and has successfully treated refractory epilepsy in AS case studies,
issues arise due to its strict adherence requirements, in addition to selective eating habits and weight issues re-
ported in patients with AS. We hypothesized that ketone ester supplementation would mimic the KD as an an-
ticonvulsant and improve the behavioral and synaptic plasticity deﬁcits in vivo. AS mice were supplemented R,
S-1,3-butanediol acetoacetate diester (KE) ad libitum for eight weeks. KE administration improved motor coor-
dination, learning and memory, and synaptic plasticity in AS mice. The KE was also anticonvulsant and altered
brain amino acid metabolism in AS treated animals. Our ﬁndings suggest that KE supplementation produces
sustained ketosis and ameliorates many phenotypes in the AS mouse model, and should be investigated further
for future clinical use.
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Angelman syndrome (AS) is a devastating neurological disorder
with a prevalence of 1 in 15,000 that currently has no treatment
(Williams et al., 2010). AS often presents with ataxia, frequent smiling
and laughter, lack of speech, and severe, debilitating seizures (Valente
et al., 2006; Pelc et al., 2008; Williams et al., 2010). It is estimated that
approximately 80% of individuals with AS have epilepsy, with difﬁculty
in controlling seizures being a primary reason for patient hospitalization
(Valente et al., 2006; Pelc et al., 2008; Thibert et al., 2009). Epilepsy inAS
is often refractory to many prescribed medications, and frequently in-
volves many seizure types (Valente et al., 2006; Pelc et al., 2008;
Thibert et al., 2009). Approximately 70% of AS cases involve deletion
within 15q11.2-q13.1 and generally exhibit increased frequency and se-
verity of seizure. The larger deletions include the gene encoding the
GABAA receptorβ3 subunit, leading to cortical hyperexcitability and sei-
zure activity. Importantly, chronic, intractable epilepsy has been shown
to cause hippocampal damage and is associated with cognitive declinete, 4001 East Fletcher Avenue,
.
ect.com).
. This is an open access article under(Helmstaedter et al., 2003). Effective anti-epileptic drugs (AEDs) are
limited in AS, and those medications are generally known to have side
effects that can alter cognition (Drane and Meador, 1996;
Campos-Castello, 2006; Mula and Trimble, 2009). Therefore, it is crucial
to ﬁnd or develop novel therapeutics to treat this aspect of the disorder.
Recent ﬁndings demonstrate an overall decrease in cortical and cer-
ebellar inhibition in AS mice, and dietary therapies may help overcome
this imbalance and affect neuronal excitability (Egawa et al., 2012;
Thibert et al., 2012; Wallace et al., 2012). Both the ketogenic diet
(KD), a high fat, low carbohydrate, moderate protein diet, and the
low-glycemic index treatment (LGIT), a high fat diet with limited carbo-
hydrates, are described as well-tolerated and successful in case reports
involving patients with AS (Valente et al., 2006; Evangeliou et al.,
2010; Stein et al., 2010; Thibert et al., 2012). Additionally, the KD has
been shown to stimulate mitochondrial biogenesis, which can improve
some of the hippocampal deﬁcits in AS mice (Bough et al., 2006; Su
et al., 2011), and enhances motor performance in neurological and neu-
rodegenerative disorders (Friedman et al., 2006; Mantis et al., 2009;
Beckett et al., 2013; Brownlow et al., 2013). However, non-pharmaco-
logical management is rarely considered and little data has been pub-
lished on dietary therapies in AS (Pelc et al., 2008; Thibert et al.,
2009), limiting additional information regarding efﬁcacy of the KD in
the overall AS population. Additionally, investigation of the KD in ASthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
39S.L. Ciarlone et al. / Neurobiology of Disease 96 (2016) 38–46speciﬁcally is hampered by individuals having selective eating habits,
weight loss, and difﬁculties gaining weight (Clayton-Smith, 1993;
Clarke and Marston, 2000).
Oral administration of ketone esters, which mimic the KD and are
precursors to ketone bodies, may help circumvent Angelman syn-
drome-speciﬁc issues, as they have been shown to signiﬁcantly elevate
blood ketones in rats (D'Agostino et al., 2013) independent of carbohy-
drate restriction (Kesl et al., 2016). Preliminary work also suggests ke-
tone esters elevate blood ketones and are generally safe and well-
tolerated in healthy human patients (Clarke et al., 2012; Kemper et al.,
2015). A number of hypotheses have sought to isolate the neuroprotec-
tive and anticonvulsant mechanism(s) underlying ketosis, including a
metabolic shift of [GABA/glutamate], resulting in increased tonic inhibi-
tion (Bough and Rho, 2007; Yudkoff et al., 2007). Therefore, the use of
therapeutics that increase the GABA/glutamate ratio may serve to
dampen overall neuronal excitability in various areas of the brain,
resulting in decreased seizure activity.
In this study, we evaluated the potential of a ketone ester (KE), R,S-
1,3-butanediol acetoacetate diester (BD-AcAc2), to induce therapeutic
ketosis in an ASmousemodel and act as an anticonvulsant. Additionally,
we examined the effects of the ketone ester on behavioral andmetabol-
ic outcomes in our mouse model. We hypothesized that supplementa-
tion of BD-AcAc2 with a standard diet would mimic results of the KD
as an anticonvulsant and a treatment for the cognitive and motor dys-
function reported in AS.
2. Materials and methods
2.1. Animals
UBE3Atm1Alb/J null mutation (AS) mice, described previously (Jiang
et al., 1998) were purchased from the Jackson Laboratory. Wild-type
(WT) and AS mice were obtained through breeding of heterozygous fe-
male mice with WTmales to produce maternally-deﬁcient AS offspring
and age-matched, wild-type littermate controls. Animals were housed
with a standard 12 h light/dark cycle and supplied with food and
water ad libitum at the University of South Florida, and were housed
in groups of three to four per cage. Experiments were performed on
12–14 week-old male and female mice. All animal testing procedures
and care followed theNIH guidelines andwere approved by theUniver-
sity of South Florida's Institutional Animal Care andUse Committee (Ap-
proval ID number A4100-01).
2.2. Ketone ester administration
4–6 week-old experimental and control mice were fasted for 8 h
prior to initial ketone ester administration and study initiation to ensure
rapid feeding compliance and to establish a similar metabolic starting
point as previously described (Poff et al., 2014). Control mice were fed
standard rodent chow (Teklad 2018) ad libitum. Mice receiving the ke-
tone supplement were administered BD-AcAc2 with their standard ro-
dent chow ad libitum. These mice received standard rodent chow
mixed at 10% BD-AcAc2 by volume and 1% saccharin for palatability
(Sigma-Aldrich) as previously described (Poff et al., 2014), which
prevented food aversion observed in initial pilot studies. The KE was
synthesized in collaboration with Savind, Seymour IL, as previously de-
scribed (D'Agostino et al., 2013). Diets were continuously monitored
and replaced twice weekly or as needed to maintain freshness for
8 weeks.
2.3. Blood and weight measurements
Blood was collected once weekly from the tail using approved
methods. Behavioral testing was not performed on these days, and
food availability was limited for 4 h and returned for 2 h prior to
blood collection. Blood glucose and β-hydroxybutyrate (BHB) weremeasuredwith the Precision Xtra™ Blood Glucose & KetoneMonitoring
System (Abbott Laboratories). Mice were weighed twice weekly for the
duration of the study and were removed from experimentation if N20%
of their initial body weight was lost. For measurement of plasma ke-
tones, blood samples (200 μl) were collected into heparinized
Eppendorf tubes. Samples were processed for the detection and quanti-
ﬁcation of BHB and acetoacetate (AcAc) at Case Western Reserve Uni-
versity, Mouse Metabolic Phenotyping Center. Blood samples were
chilled on ice for 30 s and centrifuged in a microcentrifuge (13,000g)
for 3–5min. Plasmawas removed and immediately frozen on dry ice be-
fore being stored at−80 °C. Samples were stored at−80 °C until ana-
lyzed for ketones. Internal standards of [2H6]BHB or [2H8]isopropanol
were added to the treated plasma samples (50 μl) and the BHB and
AcAc (as M + 1 of BHB) were analyzed by gas chromatography-mass
spectrometry (GC-MS) using an Agilent 5973mass spectrometer, linked
to a 6890 gas chromatograph equipped with an autosampler. Brieﬂy,
GC-MS conditions were either electron ionization (EI) mode or chemi-
cal ionization (CI) mode; the samples were detected by selected ion
monitoring as the BHB- and AcAc-trimethylsilyl derivatives (EI).2.4. Behavioral testing
Open ﬁeld behavior was assessed to determine general locomotor
activity and anxiety. Mice were placed in an acrylic chamber
(40 cm × 40 cm × 27 cm) and were allowed to explore for 15 min.
ANY-Maze animal activity system (Stoelting Co.) was used to monitor
movement and distance traveled.
Elevated plus mazewas used to assess anxiety levels in the mice. The
EPM consisted of four arms: two (30 cm× 5 cm) open,well-lit arms and
two (30 cm× 5 cm× 15 cm) enclosed arms facing each other. Each arm
attached to a common open square center platform (4.5 cm).Micewere
placed in the center platform and allowed to explore for 5min. A digital
camera (XV-BP330, Panasonic) was used to monitor activity, and ANY-
Maze animal activity system (Stoelting Co.) was used to record and an-
alyze behavior. Total time spent in open arms versus closed arms was
measured, and anxiety levels were assessed by comparing percent
time spent in the open arms.
Rotarodwas used to assess motor coordination, motor learning and
stamina. Mice were placed on a 3 cm diameter rod with an initial
rotation of 4 rpm and accelerated to 40 rpm over a maximum of 5 min
(Ugo Basile, Italy). Mice were tested for latency to fall off the rod for
four trials per day for two consecutive days.
Wire hang test was used to measure subacute muscle function and
fatigue. A horizontal wire (2 mm in diameter, 40 cm in length) was
suspended above a padded table. The animal was allowed to cling to
the middle of the wire with its forepaws for one 60 s trial, and latency
to fall was recorded.
Hindlimb clasping is used as a marker for neurological dysfunction,
including certain ataxias. The clasping test evaluated the animal's
hindlimb response during tail suspension 10 cm above their home
cage. If the hindlimbs were consistently splayed outward, away from
the abdomen, the mouse was assigned a score of 0. If one hindlimb
was retracted toward the abdomen, the animal received a score of 1. If
both hindlimbs were partially retracted toward the abdomen, it re-
ceived a score of 2. If the animal's hindlimbs were entirely retracted
and touching the abdomen it received a score of 3.
Fear conditioning was used to assess hippocampal function and
memory formation. Mice were placed in a 25 cm × 25 cm sound atten-
uation chamber with a wire grid ﬂooring. Mice were allowed to explore
the context for 3min before they received the conditioned stimulus (CS,
90 db tone) for 30 s. At the end of the 30 s, mice received a mild foot
shock (0.5 mA, unconditioned stimulus, US). After 1.5 min, the mice re-
ceived a second CS/US pairing and monitoring continued for 1.5 min
after food shock administration. 24 h following CS/US presentation,
mice were placed back into the chamber and allowed to explore for
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of lack of motion for at least 2 consecutive sec.
Novel object recognition was used to evaluate recognition memory.
Each mouse was habituated in the test arena (40 cm × 40 cm) for
10 min. 24 h following habituation, two identical objects similar in
size to themousewere placed along the center line of the arena approx-
imately 3–5 cm from theoutsidewall, andmicewere allowed to explore
for 10min. 24 h following training, a novel object replaced one of the fa-
miliar objects presented during the training session, and mice were
allowed to explore for 5 min. Animals were monitored and behavior
was quantiﬁed by video tracking (ANY-Maze, Stoelting, IL).
2.5. Audiogenic seizures
For audiogenic seizure testing, a separate cohort of micewere habit-
uated to a sound attenuation chamber for 60 s and exposed to sound
stimulation (115 dB) for 60 s or until tonic or clonic episodes occurred.
An occurrence of sound-induced seizure was deﬁned as tonic, clonic, or
tonic-clonic seizures during sound stimulation. Animals were tested
only once. Seizure testing was carried out between 1:00 PM and
6:00 PM to limit effects of diurnal variation on results.
2.6. Kainic acid injections
Seizures were induced in a separate cohort of mice by intraperitone-
al injection of kainic acid (KA) at 20mg/kg. Following injection, animals
were returned to cages where seizure severity was assessed at 5-min
intervals for up to 50 min according to a modiﬁed Racine's scale
(Dunleavy et al., 2013).
2.7. Extracellular recordings
Following behavioral testing, a cohort of mice was euthanized and
the hippocampi dissected out to be used in hippocampal LTP experi-
mentation as previously described (Trotter et al., 2013). The brain was
rapidly dissected and placed in ice-cold, oxygenated cutting solution
containing (in mM): 110 sucrose, 60 NaCl, 3 KCl, 28 NaHCO3, 1.25
NaH2PO4, 5 glucose, 0.6 ascorbate, 7 MgCl2, and 0.5 CaCl2. Hippocampal
slices (400 μm) were prepared on a vibratome and allowed to equili-
brate in a 50% cutting saline and 50% artiﬁcial cerebrospinal ﬂuid solu-
tion containing (in mM): 125 NaCl, 2.5 KCl, 26 NaHCO3, 1.25 NaH2PO4,
25 glucose, 1 MgCl2, and 2 CaCl2. Slices weremaintained in this solution
with constant 95% O2/5% CO2 perfusion for 10 min before being trans-
ferred to the brain slice recording chamber supported by nylon mesh
or maintained in a holding container. Slices were recovered for a mini-
mum of 1 h before recording. The recording chamber was held at
30° ± 0.5 °C with a ACSF ﬂow rate of 1 ml/min. Field EPSPs (fEPSPs)
were recorded from stratum radiatum in hippocampal area CA1 via
glassmicroelectrodesﬁlledwith artiﬁcial cerebrospinal ﬂuid (resistance
1–4 mΩ). Responses were generated by stimulation of Schaffer collat-
erals arising from the CA3 region. Stimulating electrodes consisted of
formvar-coated nichrome wire, which was used to deliver biphasic
stimulus pulses (1–15 V, 100 μs duration, 0.05 Hz). Delivery of stimula-
tion, controlled by pClamp 9.0 software (Molecular Devices), was via
the Digidata 1322 A interface (Molecular Devices) and a stimulus isola-
tor (model 2200; A-M Systems). Signals were ampliﬁed using a differ-
ential ampliﬁer (model 1800; A-M Systems), ﬁltered at 1 kHz, and
digitized at 10 kHz. For all experiments, baseline stimulus intensity
was set at the level that elicited ∼50% of the maximum fEPSP response
as determined from the input–output curve. The input–output relation-
shipwas determined by stimulating slices from 0 to 15mVat 0.5mV in-
crements. Short-term plasticity was measured via paired-pulse
facilitation (PPF), which was induced by stimulating slices at half-max
intensity with sequential pulses spaced at 20 ms intervals from 20 to
300 ms. LTP was induced by a theta-burst protocol, which consisted of
ﬁve trains of four pulse bursts at 200 Hz separated by 200ms, repeatedsix times with an intertrain interval of 10 s. For analysis, the last 10 min
of recording was averaged and compared.
2.8. Western blot analysis
Whole hippocampal brain tissue frommale mice was lysed on ice in
lysis buffer (radio-immunoprecipitation assay buffer supplemented
with protease/phosphatase inhibitor cocktail, Thermo Scientiﬁc). Pro-
tein concentrations were determined using the BCA Protein Assay Kit
(Thermo Scientiﬁc). Equal amounts of protein from each sample were
loaded for SDS-PAGE, and transferred to a PVDF transfer membrane.
The membranes were blocked in 0.1 M TBS with 0.1% Tween 20 and
5% nonfat milk, then incubated overnight at 4 °C with primary antibod-
ies anti-E6AP (#A300-352A, Bethyl Laboratories, Inc.), anti-GAD65/67
(#AB1511,Millipore), and anti-β-actin (#4967L, Cell Signaling Technol-
ogy) diluted in blocking solution. Membranes were washed and
incubated with anti-rabbit IgG-HRP secondary antibody (Southern Bio-
tech) diluted at 1:2000 in blocking solution. Proteins were detected
using Pierce ECL Western Blotting Substrate (Thermo Scientiﬁc) and
audioradiography. The ﬁlms were digitized and optical densities were
measured using a high-powered scanner and the software program
ImageJ (v1.46r, National Institutes of Health).
2.9. Metabolic analysis of brain amino acids
GABA and glutamate (Glu) were measured in brain homogenate at
Case Western Reserve University, Mouse Metabolic Phenotyping
Center. This approach enabled metabolites to be measured with a high
degree of sensitivity (Yang et al., 2008; Kombu et al., 2011; Zhang
et al., 2015).
2.9.1. Analytical methods
Brains were dissected immediately, frozen in liquid nitrogen within
30 s of removal and stored at−80 °C. Hippocampal sections (25–30mg
tissue)were then dissected under frozen conditions in dry ice (−80 °C).
For the isolation of metabolic intermediates the frozen tissue samples
were then homogenized using an organic solvent mixture containing
5% acetic acid and methanol (1:1; methanol to water) (Zhang et al.,
2015). Brieﬂy, frozen samples were spiked with internal standards
(0.1 μmol each): [2H6]GABA and [13C5]glutamate, and then homoge-
nized with 3 ml of cold methanol-H20 solvent mixture (1:1, v/v) using
a Polytron homogenizer.
2.9.2. GC-MS assays
Following homogenization, the homogenates were extracted
using a mixture of acetonitrile and 2-propanol (3:1), vortexed and
centrifuged for 30 min at 2500 RCF at 4 °C. Extracts were then
dried by nitrogen gas for 0.5 h or until completely dry and then
chemically derivatized using MTBSTFA +1% TBDMCS reagent (N-
methyl-N-(tert-butyldimethylsilyl) triﬂuoroacetamide +1% tert-
butyldimetheylchlorosilane, Regis Technologies, Inc. Morton Grove,
IL, USA) and reacted at 70 °C for 30 min. The derivatized products were
measured under Agilent 6890 Gas-Chromatography and Agilent 5973
Mass Spectrometry (GC-MS). A DB-17 MS capillary column
(30 m × 0.25 mm × 0.25 μm) was used in all analysis. The starting
oven temperature was set to 80 °C, the pressure was 14.82 psi, and the
ﬂow velocity was 45 cm/s. Temperature was then increased linearly to
220 °C andheld for 1min. Themass spectrometerwas in electron-impact
(EI), simmode. Ions for glutamate (m/z = 432) and GABA (m/z = 274)
were monitored and data acquisition collected and stored for further
analysis.
2.10. Statistical analysis
All data is represented as the mean ± SEM. To compute p values,
data was analyzed using Student's t-test and two-way ANOVA with
Fig. 1. R,S-1,3-butanediol acetoacetate diester (BD-AcAc2) induces ketosis, lowers glucose, and normalizes body weight in WT and AS mice. (A) BD-AcAc2 elevated whole blood β-
hydroxybutyrate (BHB) in treated WT and AS animals compared to controls. (B) WT and AS treated mice demonstrated decreased whole blood glucose compared to controls following
8 weeks of ketone ester supplementation. (C) Both plasma BHB and acetoacetate (AcAc) levels were signiﬁcantly elevated in treated compared to non-treated WT and AS animals
(n = 4/group). (D) AS mice demonstrated a signiﬁcant increase in body weight while AS KE animals had a signiﬁcant normalization in body weight that was sustained throughout the
duration of the study (WT and AS controls: n = 15; WT KE: n = 16; AS KE: n = 20; *p b 0.05, **p b 0.01 and ***p b 0.001).
Fig. 2. Ketone supplementation improves motor coordination but does not affect general locomotor activity or anxiety levels in AS mice. (A) Open ﬁeld: distance traveled. Following
8 weeks of ketone ester supplementation, mice underwent open-ﬁeld testing as a locomotor and general anxiety control for behavioral testing. Data represent the overall distance
traveled in the open ﬁeld. There were no signiﬁcant differences between experimental groups. (B) Open ﬁeld: time spent in center vs. perimeter. Data represents the ratio of time
spent (sec) in the open ﬁeld vs. the perimeter of the ﬁeld, with no signiﬁcant differences between groups. (C) Elevated plus maze: anxiety levels in WT and AS mice are unaffected
with ketone ester supplementation. Data represent percentage of total time spent in open arms of the elevated maze. There were no signiﬁcant differences between experimental
groups. (D) Average latency to fall on the accelerating rotarod was signiﬁcantly reduced in AS control animals, while ketone ester supplementation signiﬁcantly enhanced motor
performance in AS treated mice. (E) AS mice performed poorly on the wire hang task compared to WT controls, while AS KE animals demonstrate a signiﬁcant increase in the latency
to fall (WT and AS controls: n = 18; WT KE: n = 19; AS KE: n = 20). (F) Severity of the hindlimb clasping score was signiﬁcantly decreased in AS KE-treated mice (WT and AS
controls: n = 14; WT KE and AS KE: n = 15; *p b 0.05, **p b 0.01, ***p b 0.001).
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hoc tests, set at a signiﬁcance of p b 0.05 (GraphPad Prism software).
Statistical outliers that fell outside two standard deviations of the
mean were excluded from analysis. Data is also reported from both
male and female mice (Supplementary Table 1).
3. Results
3.1. Ketone supplementation lowered blood glucose, elevated blood ke-
tones, and normalized body weight in AS mice
Whole blood ketone (BHB) and glucosemeasurements were similar
at baseline, and chronic ketone supplementation resulted in elevated
ketones and lowered blood glucose in WT KE and AS KE treated mice
(Fig. 1A and B, repeated measures ANOVA, p b 0.01 and p b 0.0001;
WT vs.WT KE,WT vs. AS KE, and AS vs. AS KE p b 0.05 and p b 0.001, re-
spectively). BD-AcAc2 also signiﬁcantly increased plasma BHB (Fig. 1C,
ANOVA p b 0.05, F(3,13) = 9.156; WT vs. WT KE and AS vs. AS KE
p b 0.05) and AcAc (Fig. 1C, ANOVA p b 0.01, F(3,13) = 9.038; WT vs.
WT KE and AS vs. AS KE p b 0.05) inWT KE and AS KE compared to con-
trol animals. Standard high-carbohydrate rodent chow with ketone
supplementation also signiﬁcantly decreased body weight in AS mice
during the two-month KE treatment, which did not differ signiﬁcantly
fromWTcontrol bodyweights by the end of the study (Fig. 1D, repeated
measures ANOVA, p b 0.0001; WT vs. AS and AS vs. AS KE p b 0.001, WT
vs. AS KE p b 0.01).
3.2. Ketone supplementation had no effect on general locomotor activity or
anxiety
General locomotion and anxiety were examined in BD-AcAc2 fed
mice, in addition to WT and standard diet (SD) control animals. ThereFig. 3. BD-AcAc2 recovers associative learning and recognition memory deﬁcits observed in AS
following 8 weeks of treatment. (A) There were no signiﬁcant differences in freezing between
post-training. BD-AcAc2 administration increased the average context-dependent freezing in A
KE: n = 18; WT KE: n = 10; *p b 0.05). (C) Effect of BD-AcAc2 on recognition memory in AS
the dotted line at 50% indicates equal preference for both familiar and novel object, indicative
treatment. AS KE-treated mice demonstrated a signiﬁcant increase in the discrimination index
KE: n = 9; *p b 0.05, **p b 0.01).were no signiﬁcant alterations in general locomotor activity and anxiety
behavior in animals fed the ketone ester diet, as measured by the open
ﬁeld test (Fig. 2A and B) and elevated plus maze (Fig. 2C).3.3. Administration of a ketone ester improved motor coordination,
learning, and overall neurologic function
ASmice display abnormalities in gait, motor learning, andmotor co-
ordination, as evidenced by increased hind stride length and basewidth
and deﬁcits in rotarod, wire hang, and paw abduction tests (Jiang et al.,
1998; Van Woerden et al., 2007; Heck et al., 2008; Egawa et al., 2012;
Meng et al., 2013). Following two months of BD-AcAc2 administration,
AS KE mice demonstrated signiﬁcant improvements in rotarod perfor-
mance compared to AS controls (Fig. 2D, repeated measures ANOVA
p b 0.0001; AS vs. AS KE p b 0.01; WT vs. AS and AS KE p b 0.001). AS
mice displayed signiﬁcant deﬁcits in the wire hang task, while AS KE
diet-fed mice showed improvement in wire hang endurance, although
not to WT levels (Fig. 2E). A two-way ANOVA revealed a signiﬁcant ef-
fect of genotype (F(1,65) = 43.43, p b 0.0001; interaction of group and
treatment: p = 0.0667; Bonferroni post-hoc tests: WT vs. AS
p b 0.001; AS vs. AS KE p b 0.05; WT and WT KE vs. AS KE = p b 0.01).
All WT and WT KE mice were able to hang for the maximum time of
60 s, while 17.6% of AS and 38.8% of AS KE mice reached the maximum
trial duration. As previously reported, AS animals also demonstrated a
signiﬁcant hindlimb clasping phenotype compared to WT controls
(Egawa et al., 2012), while AS KE-fedmice showed signiﬁcant improve-
ment (Fig. 2F). A two-way ANOVA revealed a signiﬁcant effect of geno-
type (F(1,51)= 90.13, p b 0.0001) and treatment (F(1,51)= 4.16, p b 0.05)
with a signiﬁcant interaction of group and treatment (p b 0.05)
(Bonferroni post-hoc tests: WT vs. AS p b 0.001; AS vs. AS KE p b 0.01;
WT and WT KE vs. AS KE p b 0.001).mice. AS mice were trained with a standard 2-shock contextual fear conditioning protocol
experimental groups during training. (B) Contextual fear conditioning was assessed 24 h
S KE animals compared to nontreated AS mice (WT controls: n = 16; AS controls and AS
mice in the novel object recognition test. Exploratory preference 24 h following training;
of visual memory impairment. (D) Effect of BD-AcAc2 on the discrimination index post-
compared to AS controls (WT controls: n = 17; WT KE: n = 11; AS controls: n = 5; AS
43S.L. Ciarlone et al. / Neurobiology of Disease 96 (2016) 38–463.4. Ketone supplementation improves associative learning and recognition
memory in AS mice
During training, all animals showed similar levels of freezing after
presentation of the US (Fig. 3A). Changes in fear memory to the cue
were not altered in WT KE, AS KE, or control animals (data not
shown). AS KEmice had a signiﬁcant enhancement of associativemem-
ory similar to WT controls as demonstrated by increased freezing be-
havior. A two-way ANOVA revealed a signiﬁcant interaction of group
and treatment (Fig. 3B, F(1,51) = 6.98, p b 0.05; Bonferroni post-hoc
tests: WT vs. AS p b 0.05, AS vs. AS KE p b 0.05).
AS mice demonstrated impaired exploratory preference for the
novel object and KE treatment in AS mice reversed the exploratory
preference for the novel object to virtually the same level as WT mice
(Fig. 3C). A two-way ANOVA revealed a signiﬁcant effect of treatment
(F(1,34) = 9.67, p b 0.01) and signiﬁcant interaction of genotype and
treatment (F(1,34) = 8.11, p b 0.01). (Bonferroni post-hoc tests: WT vs.
AS p b 0.05, AS vs. AS KE p b 0.01). The ability to discriminate between
the familiar and novel object was calculated as the discrimination
ratio [(time spent exploring novel object – time spent exploring familiar
object)/(total time spent exploring both objects)] (Fig. 3D). A two-way
ANOVA revealed a signiﬁcant effect of treatment (F(1,35) = 5.90,
p b 0.05) and signiﬁcant interaction of genotype and treatment
(F(1,35) = 4.70, p b 0.05). Post hoc tests revealed that while there was
no signiﬁcant difference betweenWT and AS controls, KE treatment sig-
niﬁcantly increased the discrimination ratio in AS mice (ANOVA,
p b 0.05 F(3,38) = 2.697; AS vs. AS KE p b 0.05).Fig. 4. Ketone ester supplementation attenuated audiogenic and kainic acid-induced seizure ac
activity following a 115 dB sound stimulation. (B) Latency to seizure following audiogenic stim
*p b 0.05). (C) Kainic acid behavioral seizure scores in AS treated and nontreated animals.
Latency to behavioral seizure score of 2 was signiﬁcantly increased in AS KE mice (AS controls3.5. BD-AcAc2 decreases audiogenic and chemically-induced seizure
activity in AS mice
Following audiogenic stimulation, we observed seizures in 84% of
the AS mice, whereas no seizures were observed in WT animals (data
not shown). AS KE animals demonstrated a 48% reduction in seizure ac-
tivity as compared to AS controls (Fig. 4A, p b 0.05 Fisher's exact test), as
well as a signiﬁcant increase in latency to seize (Fig. 4B, p b 0.05). A sig-
niﬁcant decrease in behavioral seizure score was recorded 10 and
45 min post-kainic acid injection in AS KE vs AS control animals
(Fig. 4C, Two-way repeated measures ANOVA, Bonferroni post-hoc
tests, p b 0.01). There was also a signiﬁcant increase in the latency to a
seizure score of 2 post-injection (Fig. 4D, p b 0.05), suggesting an overall
initial delay in seizure severity.
3.6. Ketone ester supplementation in AS mice results in improvements in
early phase LTP
Using a TBS-LTP protocol, the extent of LTP, calculated by averaging
the slope values of fEPSPs recorded between 50 and 60 min after TBS,
was signiﬁcantly lower in slices from AS mice (113.2 ± 0.7) than
those from WT animals (165.7 ± 0.73) (Fig. 5C and D, ANOVA,
Bonferroni post-hoc tests, p b 0.001). Ketone ester supplementation
partially rescued impairment of LTP in area CA1 of AS KE mice (Fig. 5C
and D, 128.5 ± 0.88, p b 0.001) compared to AS mice on the standard
diet, although not to the extent ofWT animals. There were no recorded
changes in basal synaptic transmission (input-output relationship,tivity. (A) Percentage of AS KE and control animals that demonstrated behavioral seizure
ulation was signiﬁcantly increased in AS KE mice (AS controls: n = 11; AS KE: n = 13;
Scores were tabulated every 5 min (AS controls: n = 8; AS KE: n = 9; *p b 0.01). (D)
: n = 8; AS KE: n = 9; *p b 0.05).
Fig. 5.AS animals given oral ketone ester supplementation show increased LTP inductionwithout changes in synaptic transmission. (A)Normal input-output curve at hippocampal SC-CA1
synapses inWT,WT KE, AS, and AS KE-treatedmice. (B) Short-term synaptic plasticity was evaluated by the amount of PPFwith IPIs ranging from 20 to 300ms. Therewere no signiﬁcant
differences between experimental groups. (C) Long-term potentiation induced by 5 trains of theta-burst stimulation (arrow). Representative traces are shown for all groups at baseline
(black trace) and 50 min after tetanic stimulation (grey trace). Scale bar = 1 mV and 5 ms. (D) LTP induction calculated between 50 and 60 min after TBS. Data expressed as mean ±
SEM. (WT = 15 slices, n = 4 mice; WT KE= 14 slices, n = 4 mice; AS = 20 slices, n = 5 mice; AS KE = 19 slices, n = 5 mice; p b 0.001).
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Fig. 5B).
3.7. Alterations in hippocampal GAD65 and GAD67 expression and GABA/
Glutamate ratio following ketone ester administration
Hippocampal protein expression of GAD65 and GAD67 was signiﬁ-
cantly decreased in AS mice compared to WT controls by 32.8% and
49.1%, respectively (Fig. 6A and B). There were no signiﬁcant changes
in GAD65/67 in WT KE mice compared to WT controls. AS KE-fed mice
displayed signiﬁcant increases in both hippocampal GAD65 (two-way
ANOVA, p b 0.01 F(1,26) = 11.89; WT vs. AS p b 0.01, AS vs. AS KE
p b 0.001) and GAD67 (two-way ANOVA, p b 0.01 F(1,26) = 10.59; WT
vs. AS p b 0.05, AS vs. AS KE p b 0.01), comparable toWT levels. Feeding
a ketone ester diet to AS mice also resulted in a signiﬁcant increase in
the GABA/glutamate ratio when compared to standard diet-fed ASFig. 6. IncreasedGAD65/67 andGABA/glutamate ratio in theASmouse hippocampus following k
evaluated in WT, WT KE, AS, and AS KE mice by Western blotting (representative blot shown)
Experimental Procedures (n = 9 WT and AS KE, n = 8 AS, n = 4 WT KE). Expression of GAD
animals. (C) Brain amino acids GABA and glutamate were measured. The GABA/glutamate r
(*p b 0.05, **p b 0.01, ***p b 0.001).animals, similar to WT levels (Fig. 6C, two-way ANOVA, p b 0.05
F(1,13) = 11.55; WT vs. AS p b 0.05, AS vs. AS KE p b 0.01).4. Discussion
Approximately 80% of children with AS have epilepsy, with ~77% of
those individuals remaining refractory to AEDs (Thibert et al., 2009).
These patients are at a high risk of early death due to seizures, and
many suffer considerable side effects from AEDs. Accordingly, examina-
tion of alternative therapies should be prioritized. In the present study,
we examined the use of a KE to induce therapeutic ketosis and improve
behavioral phenotypes in the AS mouse model. The major ﬁndings of
this study demonstrate ketosis induced by dietary KE administration,
rather than strict adherence to a ketogenic diet, is anticonvulsant and
improves motor function. Surprisingly, we ﬁnd the KE also improvesetone ester administration. (A) Expression of GAD65 andGAD67 in the hippocampuswere
. (B) Densitometric quantiﬁcation of Western blots in (A) was performed as described in
65 and GAD67 was signiﬁcantly reduced in AS mice compared to WT controls and AS KE
atio is signiﬁcantly decreased in AS mice compared to WT controls and AS treated mice
45S.L. Ciarlone et al. / Neurobiology of Disease 96 (2016) 38–46recognition memory, associative learning, and enhances hippocampal
synaptic plasticity in AS mice.
Chronic ketone supplementation decreased blood glucose and body
weight and sustained ketosis in our AS treated mice, as evidenced by
signiﬁcantly increased plasma and whole blood ketones. In addition,
eight weeks of KE administration was sufﬁcient to normalize body
weight in AS mice via chronic ketosis. The ability of the KE to decrease
blood glucose has been reported previously (Kashiwaya et al., 2010;
Poff et al., 2014). It has also been established that ketogenic diets can
cause weight loss in overweight humans (Astrup et al., 2000; Volek et
al., 2004), and these adult AS mice are signiﬁcantly overweight com-
pared to WT controls. KEs can have an appetite suppressing effect via
an increase in the anorexigenicmetabolitemalonyl-CoA,whichmay de-
crease food intake and, in turn, decrease blood glucose and bodyweight
(Kashiwaya et al., 2010). It is also important to note that themice in this
study were fed ad libitum, therefore glucose and ketonemeasurements
could be affected by variable feeding behavior prior to weekly glucose
monitoring. Any of these factors could have an effect on the decreased
blood glucose and body weight seen in the AS KE treated animals.
In our study, KE-fed AS mice presented an overall improved behav-
ioral phenotype that correlates to an equally signiﬁcant improvement
in hippocampal synaptic function. In support of our ﬁndings, several
studies have reported similar effects of ketosis on motor and cognitive
performance in various rodent models including models of aging,
Alzheimer's disease (AD), traumatic brain injury, and amyotrophic lat-
eral sclerosis (Appelberg et al., 2009; Xu et al., 2010; Beckett et al.,
2013; Brownlow et al., 2013; Kashiwaya et al., 2013; Ari et al., 2014).
Furthermore, mitochondrial dysfunction has also been reported in the
AS mouse model, demonstrated by impaired mitochondrial structure
and a partial oxidative phosphorylation defect, resulting in increased
oxidative stress (Su et al., 2011; Llewellyn et al., 2015). Several reports
of oxidative stress have also been linked to memory deﬁcits in rodents
(Fukui et al., 2001; Silva et al., 2004), and ketones can induce synaptic
protection and prevent oxidative impairment of hippocampal LTP
(Maalouf and Rho, 2008; Abdelwahab et al., 2015). The data suggest
that incorporating ketones as alternative fuel substrates into the diet
may bypass potentialmitochondrial deﬁciencies and protect against ox-
idative stress, ameliorating some of the behavioral and altered synaptic
phenotypes in the AS mouse model.
KE supplementation produced anticonvulsant effects in AS mice in
both audiogenic- and chemically-induced paradigms, affecting inhibi-
tion. However, future studies should extend seizure monitoring follow-
ing kainic acid injections in order to record potential differences in later
seizure stages. Both synaptic GAD65 and cytosolic GAD67 are responsi-
ble for GABA synthesis, and AS mice hippocampi displayed signiﬁcant
decreases in GAD65/67 compared to WT, suggesting altered brain
amino acidmetabolism. AS KEmice demonstrated increased protein ex-
pression of both enzymes in the hippocampus, indicating a signiﬁcant
alteration in GAD activity. In order to explore the potentialmetabolic al-
terations further, we measured GABA and glutamate concentrations in
the hippocampi of AS KE and control mice, and examined the GABA/
Glu ratio as an indicator of neurotransmitter turnover. The GABA/Glu
ratio was signiﬁcantly increased in AS KE mice, suggesting the KE has
a signiﬁcant impact on brain amino acidmetabolism, and is likely affect-
ing neuronal inhibition.
Alterations inGAD, GABA, and neuronal inhibition do not solely have
an effect on seizure activity. Excitatory and inhibitory imbalances have
been reported in the AS mouse brain, which could affect synaptic func-
tion, sensory detection and integration, and result in impaired learning
and memory (Wallace et al., 2012), although recent ﬁndings suggest
GABAergic Ube3a loss speciﬁcally underlies the circuit hyperexcitability
in AS (Judson et al., 2016). Decreased hippocampal GABA resulting from
increases in GAT1, a GABA transporter, impairs learning andmemory in
mice (Hu et al., 2004), and increased GAT1 has beenmeasured in the AS
mouse cerebellum (Egawa et al., 2012). Learning triggers a rapid in-
crease in GABA content (Jasinska et al., 2010), leading to increasedGABA released from hippocampal GABAergic interneurons (Nitz and
McNaughton, 2004; Cui et al., 2008). Increased inhibitory synaptic plas-
ticity and GABA release may therefore be essential for learning and
memory tasks (Andrews-Zwilling et al., 2012). It has been suggested
that treatments that alter GABA, GABAergic interneuron function, or
GABA/glutamate ratio may be beneﬁcial for improving cognition and
synaptic plasticity in disorders such as AD (Andrews-Zwilling et al.,
2010; Andrews-Zwilling et al., 2012) and AS (Egawa et al., 2012;
Ciarlone and Weeber, 2015).
The present ﬁndings strongly suggest that KE supplementation in
addition to a standard diet induces therapeutic ketosis in AS and may
be a promising mitigation strategy for many of the devastating pheno-
types of the disorder, including seizures, motor difﬁculties, and severe
developmental delay. With limited treatment options available for
human AS, it is important to examine this therapeutic option for seizure
control and for increased cognitive acuity. Future studieswill seek to de-
termine its safety and efﬁcacy for potential future clinical trials.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2016.08.002.
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